These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23513862)

  • 1. [Resistant mechanisms against breast cancer treatment and therapeutic strategies].
    Tanizaki J; Tsurutani J
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():336-40. PubMed ID: 23513862
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 3. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
    Saxena R; Dwivedi A
    Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
    Ito Y
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 9. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 11. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 12. [Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms].
    Grell P; Svoboda M; Simícková M; Fabian P; Vyzula R
    Klin Onkol; 2009; 22(2):45-51. PubMed ID: 19522373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
    Araki K; Pegram M
    Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
    [No Abstract]   [Full Text] [Related]  

  • 15. [Targeted therapy and breast cancer: state of the art].
    Molnar-Stanciu D; Guimas V; Bensalem A; Thiery-Vuillemin A
    Pathol Biol (Paris); 2012 Aug; 60(4):254-63. PubMed ID: 22728007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
    Chandarlapaty S; Modi S
    J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
    [No Abstract]   [Full Text] [Related]  

  • 17. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced chemoresistant breast cancer responding to multidisciplinary treatment with hyperthermia, radiotherapy, and intraarterial infusion.
    Yokoyama G; Fujii T; Ogo E; Yanaga H; Toh U; Yamaguchi M; Mishima M; Takamori S; Shirouzu K; Yamana H
    Int J Clin Oncol; 2005 Apr; 10(2):139-43. PubMed ID: 15864701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity.
    Liedtke C; Kiesel L
    Maturitas; 2012 Dec; 73(4):288-94. PubMed ID: 23020990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.